<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34358460</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Month>Aug</Month><Day>10</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms.</ArticleTitle><Pagination><StartPage>109518</StartPage><MedlinePgn>109518</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2021.109518</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(21)00948-7</ELocationID><Abstract><AbstractText>We describe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T&#xa0;cell responses, soluble markers of inflammation, and antibody levels and neutralization capacity longitudinally in 70 individuals with PCR-confirmed SARS-CoV-2 infection. Participants represent a spectrum of illness and recovery, including some with persistent viral shedding in saliva and many experiencing post-acute sequelae of SARS-CoV-2 infection (PASC). T&#xa0;cell responses remain stable for up to 9&#xa0;months. Whereas the magnitude of early CD4<sup>+</sup> T&#xa0;cell immune responses correlates with severity of initial infection, pre-existing lung disease is independently associated with higher long-term SARS-CoV-2-specific CD8<sup>+</sup> T&#xa0;cell responses. Among participants with PASC 4&#xa0;months following coronavirus disease 2019 (COVID-19) symptom onset, we observe a lower frequency of CD8<sup>+</sup> T&#xa0;cells expressing CD107a, a marker of degranulation, in response to Nucleocapsid (N) peptide pool stimulation, and a more rapid decline in the frequency of N-specific interferon-&#x3b3;-producing CD8<sup>+</sup> T&#xa0;cells. Neutralizing antibody levels strongly correlate with SARS-CoV-2-specific CD4<sup>+</sup> T&#xa0;cell responses.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peluso</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deitchman</LastName><ForeName>Amelia N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torres</LastName><ForeName>Leonel</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA; Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iyer</LastName><ForeName>Nikita S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munter</LastName><ForeName>Sadie E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nixon</LastName><ForeName>Christopher C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donatelli</LastName><ForeName>Joanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thanh</LastName><ForeName>Cassandra</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Saki</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hakim</LastName><ForeName>Jill</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turcios</LastName><ForeName>Keirstinne</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janson</LastName><ForeName>Owen</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoh</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tai</LastName><ForeName>Viva</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Yanel</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fehrman</LastName><ForeName>Emily A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spinelli</LastName><ForeName>Matthew A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gandhi</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trinh</LastName><ForeName>Lan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Monogram Biosciences, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wrin</LastName><ForeName>Terri</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Monogram Biosciences, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petropoulos</LastName><ForeName>Christos J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Monogram Biosciences, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aweeka</LastName><ForeName>Francesca T</ForeName><Initials>FT</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez-Barraquer</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA; Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelly</LastName><ForeName>J Daniel</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Jeffrey N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deeks</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greenhouse</LastName><ForeName>Bryan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA; Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rutishauser</LastName><ForeName>Rachel L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Monogram Biosciences, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henrich</LastName><ForeName>Timothy J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Monogram Biosciences, Inc., South San Francisco, CA, USA. Electronic address: timothy.henrich@ucsf.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI158013</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AI144048</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AI060530</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AI167648</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AI027763</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HD068174</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI141003</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>L30 AI126521</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AI146268</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>medRxiv. 2021 Mar 01:2021.02.26.21252308. doi: 10.1101/2021.02.26.21252308</RefSource><PMID Version="1">33688685</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017201" MajorTopicYN="N">Virus Shedding</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">PASC</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">T cell</Keyword><Keyword MajorTopicYN="N">immunity</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">post-acute sequelae of SARS-CoV-2 infection</Keyword></KeywordList><CoiStatement>Declaration of interests L.T., T.W., and C.J.P. are employees of Monogram Biosciences, a division of LabCorp. T.J.H. reports grants from Merck, Gilead Biosciences, and Bristol-Myers Squibb outside the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>6</Day><Hour>20</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>8</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34358460</ArticleId><ArticleId IdType="pmc">PMC8342976</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2021.109518</ArticleId><ArticleId IdType="pii">S2211-1247(21)00948-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Amanat F., Stadlbauer D., Strohmeier S., Nguyen T.H.O., Chromikova V., McMahon M., Jiang K., Arunkumar G.A., Jurczyszak D., Polanco J., et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat. Med. 2020;26:1033&#x2013;1036.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8183627</ArticleId><ArticleId IdType="pubmed">32398876</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun J., Loyal L., Frentsch M., Wendisch D., Georg P., Kurth F., Hippenstiel S., Dingeldey M., Kruse B., Fauchere F., et al. SARS-CoV-2-reactive T&#xa0;cells in healthy donors and patients with COVID-19. Nature. 2020;587:270&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">32726801</ArticleId></ArticleIdList></Reference><Reference><Citation>Breton G., Mendoza P., H&#xe4;ggl&#xf6;f T., Oliveira T.Y., Schaefer-Babajew D., Gaebler C., Turroja M., Hurley A., Caskey M., Nussenzweig M.C. Persistent cellular immunity to SARS-CoV-2 infection. J.&#xa0;Exp. Med. 2021;218:e20202515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7845919</ArticleId><ArticleId IdType="pubmed">33533915</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A., Bernabei R., Landi F., Gemelli Against COVID-19 Post-Acute Care Study Group Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020;324:603&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Chamie G., Marquez C., Crawford E., Peng J., Petersen M., Schwab D., Schwab J., Martinez J., Jones D., Black D., et al. Community Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 Disproportionately Affects the Latinx Population During Shelter-in-Place in San Francisco. Clin. Infect. Dis. 2020;2020:ciaa1234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7499499</ArticleId><ArticleId IdType="pubmed">32821935</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X., Pan Z., Yue S., Yu F., Zhang J., Yang Y., Li R., Liu B., Yang X., Gao L., et al. Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19. Signal Transduct. Target. Ther. 2020;5:180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7464057</ArticleId><ArticleId IdType="pubmed">32879307</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Zuiani A., Fischinger S., Mullur J., Atyeo C., Travers M., Lelis F.J.N., Pullen K.M., Martin H., Tong P., et al. Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production. Cell. 2020;183:1496&#x2013;1507.e16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7608032</ArticleId><ArticleId IdType="pubmed">33171099</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia W.N., Zhu F., Ong S.W.X., Young B.E., Fong S.-W., Le Bert N., Tan C.W., Tiu C., Zhang J., Tan S.Y., et al. Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. Lancet Microbe. 2021;2:e240&#x2013;e249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7987301</ArticleId><ArticleId IdType="pubmed">33778792</ArticleId></ArticleIdList></Reference><Reference><Citation>Dan J.M., Mateus J., Kato Y., Hastie K.M., Yu E.D., Faliti C.E., Grifoni A., Ramirez S.I., Haupt S., Frazier A., et al. Immunological memory to SARS-CoV-2 assessed for up to 8&#xa0;months after infection. Science. 2021;371:eabf4063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7919858</ArticleId><ArticleId IdType="pubmed">33408181</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta S.D., Talwar A., Lee J.T. A Proposed Framework and Timeline of the Spectrum of Disease Due to SARS-CoV-2 Infection: Illness Beyond Acute Infection and Public Health Implications. JAMA. 2020;324:2251&#x2013;2252.</Citation><ArticleIdList><ArticleId IdType="pubmed">33206133</ArticleId></ArticleIdList></Reference><Reference><Citation>de Melo G.D., Lazarini F., Levallois S., Hautefort C., Michel V., Larrous F., Verillaud B., Aparicio C., Wagner S., Gheusi G., et al. COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters. Sci. Transl. Med. 2021;13:eabf8396.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8158965</ArticleId><ArticleId IdType="pubmed">33941622</ArticleId></ArticleIdList></Reference><Reference><Citation>Drew D.A., Nguyen L.H., Steves C.J., Menni C., Freydin M., Varsavsky T., Sudre C.H., Cardoso M.J., Ourselin S., Wolf J., et al. Rapid implementation of mobile technology for real-time epidemiology of COVID-19. Science. 2020;368:1362&#x2013;1367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7200009</ArticleId><ArticleId IdType="pubmed">32371477</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C., Wang Z., Lorenzi J.C.C., Muecksch F., Finkin S., Tokuyama M., Cho A., Jankovic M., Schaefer-Babajew D., Oliveira T.Y., et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591:639&#x2013;644.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Grifoni A., Weiskopf D., Ramirez S.I., Mateus J., Dan J.M., Moderbacher C.R., Rawlings S.A., Sutherland A., Premkumar L., Jadi R.S., et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020;181:1489&#x2013;1501.e15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7237901</ArticleId><ArticleId IdType="pubmed">32473127</ArticleId></ArticleIdList></Reference><Reference><Citation>Gudbjartsson D.F., Norddahl G.L., Melsted P., Gunnarsdottir K., Holm H., Eythorsson E., Arnthorsson A.O., Helgason D., Bjarnadottir K., Ingvarsson R.F., et al. Humoral Immune Response to SARS-CoV-2 in Iceland. N.&#xa0;Engl. J. Med. 2020;383:1724&#x2013;1734.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7494247</ArticleId><ArticleId IdType="pubmed">32871063</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellmuth J., Barnett T.A., Asken B.M., Kelly J.D., Torres L., Stephens M.L., Greenhouse B., Martin J.N., Chow F.C., Deeks S.G., et al. Persistent COVID-19-associated neurocognitive symptoms in non-hospitalized patients. J.&#xa0;Neurovirol. 2021;27:191&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7852463</ArticleId><ArticleId IdType="pubmed">33528824</ArticleId></ArticleIdList></Reference><Reference><Citation>Henrich T.J., Hatano H., Bacon O., Hogan L.E., Rutishauser R., Hill A., Kearney M.F., Anderson E.M., Buchbinder S.P., Cohen S.E., et al. HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. PLoS Med. 2017;14:e1002417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5675377</ArticleId><ArticleId IdType="pubmed">29112956</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Huang L., Wang Y., Li X., Ren L., Gu X., Kang L., Guo L., Liu M., Zhou X., et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowitdamrong E., Puthanakit T., Jantarabenjakul W., Prompetchara E., Suchartlikitwong P., Putcharoen O., Hirankarn N. Antibody responses to SARS-CoV-2 in patients with differing severities of coronavirus disease 2019. PLoS ONE. 2020;15:e0240502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7546485</ArticleId><ArticleId IdType="pubmed">33035234</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Bert N., Clapham H.E., Tan A.T., Chia W.N., Tham C.Y.L., Lim J.M., Kunasegaran K., Tan L.W.L., Dutertre C.-A., Shankar N., et al. Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection. J.&#xa0;Exp. Med. 2021;218:e20202617.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7927662</ArticleId><ArticleId IdType="pubmed">33646265</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei Q., Li Y., Hou H.-Y., Wang F., Ouyang Z.-Q., Zhang Y., Lai D.-Y., Banga Ndzouboukou J.-L., Xu Z.-W., Zhang B., et al. Antibody dynamics to SARS-CoV-2 in asymptomatic COVID-19 infections. Allergy. 2020;76:551&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7675426</ArticleId><ArticleId IdType="pubmed">33040337</ArticleId></ArticleIdList></Reference><Reference><Citation>Long Q.-X., Tang X.-J., Shi Q.-L., Li Q., Deng H.-J., Yuan J., Hu J.-L., Xu W., Zhang Y., Lv F.-J., et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat. Med. 2020;26:1200&#x2013;1204.</Citation><ArticleIdList><ArticleId IdType="pubmed">32555424</ArticleId></ArticleIdList></Reference><Reference><Citation>Morley D., Lambert J.S., Hogan L.E., De Gascun C., Redmond N., Rutishauser R.L., Thanh C., Gibson E.A., Hobbs K., Bakkour S., et al. Rapid development of HIV elite control in a patient with acute infection. BMC Infect. Dis. 2019;19:815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6749690</ArticleId><ArticleId IdType="pubmed">31533639</ArticleId></ArticleIdList></Reference><Reference><Citation>Naaber P., Hunt K., Pesukova J., Haljasm&#xe4;gi L., Rumm P., Peterson P., Hololejenko J., Eero I., J&#xf5;gi P., Toompere K., Sepp E. Evaluation of SARS-CoV-2 IgG antibody response in PCR positive patients: Comparison of nine tests in relation to clinical data. PLoS ONE. 2020;15:e0237548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7591045</ArticleId><ArticleId IdType="pubmed">33108380</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., Cook J.R., Nordvig A.S., Shalev D., Sehrawat T.S., et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., Kelly J.D., Lu S., Goldberg S.A., Davidson M.C., Mathur S., Durstenfeld M.S., Spinelli M.A., Hoh R., Tai V., et al. Rapid implementation of a cohort for the study of post-acute sequelae of SARS-CoV-2 infection/COVID-19. medRxiv. 2021</Citation></Reference><Reference><Citation>Peng Y., Mentzer A.J., Liu G., Yao X., Yin Z., Dong D., Dejnirattisai W., Rostron T., Supasa P., Liu C., et al. Broad and strong memory CD4+ and CD8+ T&#xa0;cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat. Immunol. 2020;21:1336&#x2013;1345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611020</ArticleId><ArticleId IdType="pubmed">32887977</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilarowski G., Lebel P., Sunshine S., Liu J., Crawford E., Marquez C., Rubio L., Chamie G., Martinez J., Peng J., et al. Performance Characteristics of a Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Antigen Detection Assay at a Public Plaza Testing Site in San Francisco. J.&#xa0;Infect. Dis. 2021;223:1139&#x2013;1144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7799021</ArticleId><ArticleId IdType="pubmed">33394052</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson S., Hirsch J.S., Narasimhan M., Crawford J.M., McGinn T., Davidson K.W., Barnaby D.P., Becker L.B., Chelico J.D., Cohen S.L., et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020;323:2052&#x2013;2059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7177629</ArticleId><ArticleId IdType="pubmed">32320003</ArticleId></ArticleIdList></Reference><Reference><Citation>Rydyznski Moderbacher C., Ramirez S.I., Dan J.M., Grifoni A., Hastie K.M., Weiskopf D., Belanger S., Abbott R.K., Kim C., Choi J., et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. Cell. 2020;183:996&#x2013;1012.e19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7494270</ArticleId><ArticleId IdType="pubmed">33010815</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakanashi D., Asai N., Nakamura A., Miyazaki N., Kawamoto Y., Ohno T., Yamada A., Koita I., Suematsu H., Hagihara M., et al. Comparative evaluation of nasopharyngeal swab and saliva specimens for the molecular detection of SARS-CoV-2 RNA in Japanese patients with COVID-19. J.&#xa0;Infect. Chemother. 2021;27:126&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7524660</ArticleId><ArticleId IdType="pubmed">33060046</ArticleId></ArticleIdList></Reference><Reference><Citation>Scully E.P., Rutishauser R.L., Simoneau C.R., Delagr&#xe8;verie H., Euler Z., Thanh C., Li J.Z., Hartig H., Bakkour S., Busch M., et al. Inconsistent HIV reservoir dynamics and immune responses following anti-PD-1 therapy in cancer patients with HIV infection. Ann. Oncol. 2018;29:2141&#x2013;2142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6225895</ArticleId><ArticleId IdType="pubmed">30032204</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekine T., Perez-Potti A., Rivera-Ballesteros O., Str&#xe5;lin K., Gorin J.-B., Olsson A., Llewellyn-Lacey S., Kamal H., Bogdanovic G., Muschiol S., et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020;183:158&#x2013;168.e14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7427556</ArticleId><ArticleId IdType="pubmed">32979941</ArticleId></ArticleIdList></Reference><Reference><Citation>Seow J., Graham C., Merrick B., Acors S., Pickering S., Steel K.J.A., Hemmings O., O&#x2019;Byrne A., Kouphou N., Galao R.P., et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat. Microbiol. 2020;5:1598&#x2013;1607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7610833</ArticleId><ArticleId IdType="pubmed">33106674</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan A.T., Linster M., Tan C.W., Le Bert N., Chia W.N., Kunasegaran K., Zhuang Y., Tham C.Y.L., Chia A., Smith G.J.D., et al. Early induction of functional SARS-CoV-2-specific T&#xa0;cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Rep. 2021;34:108728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7826084</ArticleId><ArticleId IdType="pubmed">33516277</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde M.W., Kim S.S., Lindsell C.J., Billig Rose E., Shapiro N.I., Files D.C., Gibbs K.W., Erickson H.L., Steingrub J.S., Smithline H.A., et al. Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network - United States, March-June 2020. MMWR Morb. Mortal. Wkly. Rep. 2020;69:993&#x2013;998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392393</ArticleId><ArticleId IdType="pubmed">32730238</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L., Hall T., Ssewanyana I., Oulton T., Patterson C., Vasileva H., Singh S., Affara M., Mwesigwa J., Correa S., et al. Optimisation and standardisation of a multiplex immunoassay of diverse Plasmodium falciparum antigens to assess changes in malaria transmission using sero-epidemiology. Wellcome Open Res. 2020;4:26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7255915</ArticleId><ArticleId IdType="pubmed">32518839</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao L., Wang G.-L., Shen Y., Wang Z.-Y., Zhan B.-D., Duan L.-J., Lu B., Shi C., Gao Y.-M., Peng H.-H., et al. Persistence of Antibody and Cellular Immune Responses in COVID-19 patients over Nine Months after Infection. J.&#xa0;Infect. Dis. 2021;2021:jiab255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8243600</ArticleId><ArticleId IdType="pubmed">33978754</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J., Yuan Q., Wang H., Liu W., Liao X., Su Y., Wang X., Yuan J., Li T., Li J., et al. Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin. Infect. Dis. 2020;71:2027&#x2013;2034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184337</ArticleId><ArticleId IdType="pubmed">32221519</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou R., To K.K.-W., Wong Y.-C., Liu L., Zhou B., Li X., Huang H., Mo Y., Luk T.-Y., Lau T.T.-K., et al. Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses. Immunity. 2020;53:864&#x2013;877.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7402670</ArticleId><ArticleId IdType="pubmed">32791036</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>